CELLECTAR, Inc.

MADISON, WI · CIK 0001212587 · Biotech · Public

Phospholipid Drug Conjugate (PDC) platform for targeted cancer therapeutics

cellectar.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$2.7M
1 Form D · Feb 2010
200 months since last filing
Contracts
—
No federal contracts on record
Patents
11
7 granted · 4 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$2,720,985
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1891PLEOPHARMA, INC.—$17M
1892D2G ONCOLOGY, INC.—$6.6M
1893OCATA THERAPEUTICS, INC.——
1894CELLECTAR, Inc.—$2.7M
1895SUNNYLIFE PHARMA INC.——
1896NASH HOLDINGS, LLC—$1.4M
1897Cybele Microbiome Inc—$1.6M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 7 related persons
  • William ClarkeDirector · Executive Officer
  • Charles HarwoodDirector
  • Thomas MackieDirector
  • Bruce NevaiserDirector
  • Neal SandyExecutive Officer
  • Terry SivesindDirector
  • Jamey WeichertDirector · Executive Officer

Patents

USPTO · 7 granted of 11

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.